What condition is associated with the use of Fen-Phen and Redux?

The use of Fen-Phen (a combination of fenfluramine and phentermine) and Redux, which contains dexfenfluramine, was primarily associated with the risk of developing pulmonary hypertension, specifically a rare form called primary pulmonary hypertension. This condition involves increased blood pressure in the pulmonary arteries, leading to significant cardiovascular issues and respiratory difficulties.

The medications were initially marketed for weight loss, thus linking them to obesity treatment, but the serious side effects, including pulmonary hypertension, resulted in their removal from the market. The connection between Fen-Phen and pulmonary hypertension is well-documented in medical literature, emphasizing the severe risk posed by these drugs.

While obesity is the original intended use for these medications, it is pulmonary hypertension that emerged as a critical adverse effect. Diabetes and osteoporosis are not directly associated with Fen-Phen or Redux, reinforcing that pulmonary hypertension is indeed the primary condition linked to these drugs.